AI Article Synopsis
- The study assessed two radioimmunoconjugates, In-DTPA-trastuzumab and Lu-DOTA-trastuzumab, focusing on how different chelating agents affect their properties and binding to HER2 tumor cells.
- Despite the variations in chelating agents, the molar ratios (1:10 and 1:20) did not compromise the integrity, labeling process, or stability of the antibodies.
- However, notable differences were found in the lipophilicity and binding efficiency to HER2 positive SK-BR-3 cells, indicating that selecting the right chelating agent and ratio is crucial for developing effective radioimmunoconjugates.
Article Abstract
In the present work, the radioimmunoconjugates In-DTPA-trastuzumab and Lu-DOTA-trastuzumab were evaluated regarding the influence of the chelating agents on the physical-chemical parameters and human epidermal growth factor receptor 2 (HER2) tumor cell binding. Data showed that both chelating agents, at predetermined molar ratios (antibody:chelator - 1:10 and 1:20), did not influence the immunoconjugates integrity, the radiolabeling process and the radiolabeled antibodies stability. However, differences were observed in the lipophilic feature between DOTA and DTPA radioimmunoconjugates and in the specific binding to SK-BR-3 tumor cells (HER2 positive). Therefore, this study showed the importance of assessing the influence of chelating agents and their molar ratios in the development process of radioimmunoconjugates.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bmc.2021.115996 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!